Netflix marathons might make you miserable
408 people aged 18 and over were recruited through an online crowdsourcing marketplace and completed a survey regarding their viewing habits. The results were examined for potential TV
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Major amendments to the protocol include the addition of talimogene laherparepvec (Imlygic) as an option for use as comparator. The amended protocol also extends eligibility to include Stage